|
Neonatal Intensive Care Drug Manual
|
bet | 571/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
Evidence summary
|
Efficacy:
ARC (ANZCOR) treatment recommendations for supraventricular tachycardia: Sotalol is not considered as a treatment option for acute treatment of infants with SVT. Adenosine is the drug of choice. Alternative drugs are procainamide, [Class B; LOE IV] digoxin, a beta blocker or a calcium channel blocker (calcium channel blockers should not be used to treat SVT in infants).1
eTG Complete (Therapeutic Guidelines November 2015): There is no infant recommendation. Sotalol is a treatment option for:
Paroxysmal supraventricular tachycardia (oral);
Nonsustained ventricular tachycardia if associated with symptoms or haemodynamic compromise (oral);
Sustained ventricular tachycardia including if haemodynamically unstable (IV) and for ongoing treatment (oral).
|
|
| |